Browse > Article
http://dx.doi.org/10.7314/APJCP.2014.15.19.8435

Prognostic Values of VEGF and Endostatin with Malignant Pleural Effusions in Patients with Lung Cancer  

Zhang, Yu (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Yu, Li-Ke (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Lu, Guo-Jun (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Xia, Ning (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Xie, Hai-Yan (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Hu, Wei (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Hao, Ke-Ke (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Xu, Chun-Hua (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Qian, Qian (First Department of Respiratory Medicine, Nanjing Chest Hospital)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.15, no.19, 2014 , pp. 8435-8440 More about this Journal
Abstract
Aims: Angiogenesis is important in malignant pleural effusion (MPE) formation and it is regulated by a number of pro- and anti-angiogenic cytokines. The purpose of this study was to evaluate the prognostic value of angiogenic factor vascular endothelial growth factor (VEGF) and angiogenesis inhibitor endostatin in lung cancer patients with MPE, and investigate the relationship between these two kinds of agent. Methods: Using enzyme-linked immunoadsorbent assay, the concentrations of VEGF and endostatin were measured in pleural effusions (PE) and serum from a total of 70 lung cancer patients with MPE and 20 patients with tuberculosis. Results: Compared to patients with tuberculosis, the levels of VEGF and endostatin in both PE and serum were significantly higher in patients with lung cancer. There were statistically significant correlations between VEGF levels in PE and serum (r=0.696, p<0.001), endostatin levels in PE and serum (r=0.310, p=0.022), and VEGF and endostatin levels in PE (r=0.287, p=0.019). Cox multivariate analysis revealed that elevated pleural VEGF and endostatin levels and serum endostatin level were independent predictors of shorter overall survival. Conclusion: Both pro- and anti-angiogenic factors are likely contributors to PE formation. Our results suggest that the levels of VEGF and endostatin in PE, together with endostatin in serum, may be potential prognostic parameters for lung cancer patients with MPE.
Keywords
Malignant pleural effusion; lung cancer; prognosis; vascular endothelial growth factor; endostatin;
Citations & Related Records
Times Cited By KSCI : 2  (Citation Analysis)
연도 인용수 순위
1 Chakra M, Pujol JL, Lamy PJ, et al (2008). Circulating serum vascular endothelial growth factor is not a prognostic factor of non-small cell lung cancer. J Thorac Oncol, 3, 1119-26.   DOI
2 Bradshaw M, Mansfield A, Peikert T (2013). The role of vascular endothelial growth factor in the pathogenesis, diagnosis and treatment of malignant pleural effusion. Curr Oncol Rep, 15, 207-16.   DOI
3 Davies H E, Lee Y C G (2013). Management of malignant pleural effusions: questions that need answers. Curr Opin Pulm Med, 19, 374-9.   DOI
4 Chen X, Liu Y, Yin Y, et al (2012). Recombinant human endostatin (endostar) decreased recurrent ascites, pleural fluid and ascitic VEGF in a case of advanced mesothelioma. J Chemother, 24, 231-6.   DOI
5 Chen Y, Liang B, Zhao Y J, et al (2012). Transcription expression and clinical significance of vascular endothelial growth factor mRNA and endostatin mRNA in pleural effusions of patients with lung cancer. Diagn Cytopathol, 40, 287-91.   DOI
6 Choi J H, Chul Kim H, Lim H Y, et al (2001). Vascular endothelial growth factor in the serum of patients with nonsmall cell lung cancer: correlation with platelet and leukocyte counts. Lung Cancer, 33, 171-79.   DOI
7 Dong XP, Xiao TH, Dong H, et al (2013). Endostar combined with cisplatin inhibits tumor growth and lymphatic metastasis of lewis lung carcinoma xenografts in mice. Asian Pac J Cancer Prev, 14, 3079-83.   DOI
8 Du N, Li X, Li F, et aln (2013). Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep, 29, 2332-40.
9 Fiorelli A, Vicidomini G, Di Domenico M, et al (2011). Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. Interact Cardiovasc Thorac Surg, 12, 420-4.   DOI
10 Goldstraw P, Crowley J, Chansky K, et al (2007). The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. J Thorac Oncol, 2, 706-14.   DOI   ScienceOn
11 Hsu I L, Su WC, Yan JJ, et al (2009). Angiogenetic biomarkers in non-small cell lung cancer with malignant pleural effusion: correlations with patient survival and pleural effusion control. Lung Cancer, 65, 371-6.   DOI
12 Hama M, Komatsu Y, Hachiya T (2011). A case of lung cancer showing marked reduction of pleural effusion by bevacizumab in combination with carboplatin and paclitaxel. Gan to kagaku ryoho. Gan To Kagaku Ryoho, 38, 1877-9.
13 Hasegawa Y, Takanashi S, Okudera K, et al (2005). Vascular endothelial growth factor level as a prognostic determinant of small cell lung cancer in Japanese patients. Intern Med (Tokyo, Japan), 44, 26-4.   DOI
14 Kaya A, Ciledag A, Gulbay B E, et al (2004). The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med, 98, 632-6.   DOI
15 Heffner JE (2008). Diagnosis and management of malignant pleural effusions. Respirology, 13, 5-20.
16 Iizasa T, Chang H, Suzuki M, et al (2004). Overexpression of Collagen XVIII is associated with poor outcome and elevated levels of circulating serum endostatin in non-small cell lung cancer. Clin Cancer Res, 10, 5361-6.   DOI   ScienceOn
17 Ishimoto O, Saijo Y, Narumi K, et al (2002). High level of vascular endothelial growth factor in hemorrhagic pleural effusion of cancer. Oncology, 63, 70-5.   DOI
18 Kitamura K, Kubota K, Ando M, et al (2013). Bevacizumab plus chemotherapy for advanced non-squamous non-smallcell lung cancer with malignant pleural effusion. Cancer Chemother Pharmacol, 71, 457-61.   DOI
19 Koniari I, Koletti B, Apostolakis E (2011). Vascular endothelial growth factor with tumour growth factor-${\beta}$, endostatin, proteinases or cytokines might be useful for differential diagnosis of pleural effusions. Interact Cardiovasc Thorac Surg, 12, 424-5.   DOI
20 Memon A, Zawadzki Z A (1981). Malignant effusions: diagnostic evaluation and therapeutic strategy. Curr Probl Cancer, 5, 1-30.
21 Laack E, Kohler A, Kugler C, et al (2002). Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer. Ann Oncol, 13, 1550-7.   DOI
22 Ma X, Yao Y, Yuan D, et al (2012). Recombinant human endostatin endostar suppresses angiogenesis and lymphangiogenesis of malignant pleural effusion in mice. PloS One, 7, e53449.   DOI
23 Ruiz E, Aleman C, Alegre J, et al (2005). Angiogenic factors and angiogenesis inhibitors in exudative pleural effusions. Lung, 183, 185-95.   DOI
24 Macchiarini P, Fontanini G, Squartini F, et al (1992). Relation of neovascularisation to metastasis of non-small-cell lung cancer. Lancet, 340, 145-6.   DOI   ScienceOn
25 O'Reilly M S, Boehm T, Shing Y, et al (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-85.   DOI   ScienceOn
26 Roberts M E, Neville E, Berrisford R G, et al (2010). Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax, 65, ii32-0.
27 Sack U, Hoffmann M, Zhao XJ, et al (2005). Vascular endothelial growth factor in pleural effusions of different origin. Eur Respir J, 25, 600-04.   DOI   ScienceOn
28 Salven P, Orpana A, Joensuu H (1999). Leukocytes and platelets of patients with cancer contain high levels of vascular endothelial growth factor. Clin Cancer Res, 5, 487-91.
29 Skovseth D K, Veuger M J T, Sorensen D R, et al (2005). Endostatin dramatically inhibits endothelial cell migration, vascular morphogenesis, and perivascular cell recruitment in vivo. Blood, 105, 1044-51.
30 Yanagawa H, Takeuchi E, Suzuki Y, et al (1999). Vascular endothelial growth factor in malignant pleural effusion associated with lung cancer. Cancer Immunol Immunother, 48, 396-00.   DOI   ScienceOn
31 Song XY, Zhou SJ, Xiao N, et al (2013). Research on the relationship between serum levels of inflammatory cytokines and non-small cell lung cancer. Asian Pac J Cancer Prev, 14, 4765-8.   DOI   ScienceOn
32 Zhang Y, Yu LK, Xia N (2012). Evaluation of serum and pleural levels of endostatin and vascular epithelial growth factor in lung cancer patients with pleural effusion. Asian Pac J Trop Med, 5, 239-42.   DOI
33 Sumi M, Kagohashi K, Satoh H, et al (2003). Endostatin levels in exudative pleural effusions. Lung, 181, 329-34.   DOI
34 Suzuki M, Iizasa T, Ko E, et al (2002). Serum endostatin correlates with progression and prognosis of non-small cell lung cancer. Lung Cancer, 35, 29-4.   DOI
35 Zebrowski BK, Yano S, Liu W, et al (1999). Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions. Clin Cancer Res, 5, 3364-8.
36 Zhou WB, Bai M, Jin Y (2009). Diagnostic value of vascular endothelial growth factor and endostatin in malignant pleural effusions. Int J Tuberc Lung Dis, 13, 381-6.
37 Ziora D, Sielska-Spytek E, Dworniczak S, et al (2002). VEGF (vascular endothelial growth factor) concentration in serum and pleural fluid of patients with pleural malignancy and pleural tuberculosis. Pneumonol Alergol Pol, 70, 458-67.